Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-16T07:30:26.266Z Has data issue: false hasContentIssue false
  • English
  • Français

Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis

Published online by Cambridge University Press:  13 May 2013

Jia Wei Zheng
Jia Wei Zheng*
Affiliation:
Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
*
Correspondence to: Jia Wei Zheng, Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Tel: 0086 21 23271063; Fax: 0086 21 63121780; E-mail: zhjw@omschina.org.cn
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Letter to the Editor
Information
Cardiology in the Young , Volume 23 , Issue 5 , October 2013 , pp. 780
Copyright
Copyright © Cambridge University Press 2013 

Dear Editor,

I read the article entitled “Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis” published in Cardiol Young Reference Dyme, Thampan, Han, Nyirenda, Kotb and Shin 1 with great interest. I absolutely agree with the authors’ opinion and the conclusions of the retrospective study: most of the patients with infantile haemangioma can be safely and effectively treated on an outpatient basis; other expensive testing is unnecessary during pre-treatment screening when physical examinations including an electrocardiogram and an echocardiogram are normal.

We have treated more than 150 patients with infantile haemangioma in the head and neck region at our institution since October 2008. Initially, the patients were hospitalised for 7–10 days; they continued medication at home and revisited every 2 weeks.Reference Qin, Liu, Li, Zhou, Yang and Zheng 2 Owing to the safety of the treatment modality and the patients’ good tolerance, all patients referring to our institution are now treated at the outpatient clinic. When a baseline evaluation including a blood test, an electrocardiogram, and an echocardiogram is normal, propranolol (10 mg/tablet) is prescribed to the parents. The parents are instructed in detail on how to administer the drug to the child and what and how to monitor in the child after medication; they were also advised to visit the doctor regularly.

One concern is the larger dose the authors used in the study (3 mg/kg/day). Low-dose propranolol is effective and safe for treating problematic proliferating infantile haemangioma.Reference Tan, Itinteang and Leadbitter 3 Most physicians recommend a target dosage of 2 mg/kg/day in divided doses, although the appropriate dose and dosing regimens are to be further explored.Reference Drolet, Frommelt and Chamlin 4

References

1. Dyme, JL, Thampan, A, Han, EJ, Nyirenda, TL, Kotb, ME, Shin, HT. Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. Cardiol Young 2012; 22: 424–429.Google Scholar
2. Qin, ZP, Liu, XJ, Li, KL, Zhou, Q, Yang, XJ, Zheng, JW. Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety. Zhonghua Yi Xue Za Zhi 2009; 89: 3130–3134.Google Scholar
3. Tan, ST, Itinteang, T, Leadbitter, P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 2011; 64: 292–299.Google Scholar
4. Drolet, BA, Frommelt, PC, Chamlin, SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131: 128–140.CrossRefGoogle ScholarPubMed